Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Clover Biopharmaceuticals Ltd. ( (HK:2197) ) is now available.
Clover Biopharmaceuticals has initiated a Phase 2 clinical trial in Australia for its protein-based combination respiratory vaccine candidates SCB-1022 (targeting RSV and hMPV) and SCB-1033 (targeting RSV, hMPV and PIV3), both built on its prefusion-stabilized F (PreF)-Trimer subunit antigens using the company’s Trimer-Tag technology. The randomized, observer-blinded, multi-center study will enroll up to 420 adults aged 60 to 85, comparing the two candidates against placebo to evaluate safety, reactogenicity and immunogenicity, marking a key step in Clover’s efforts to expand its respiratory vaccine pipeline for older adults and potentially strengthen its competitive position in the global vaccine market.
The most recent analyst rating on (HK:2197) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Clover Biopharmaceuticals Ltd. stock, see the HK:2197 Stock Forecast page.
More about Clover Biopharmaceuticals Ltd.
Clover Biopharmaceuticals Ltd. is a biopharmaceutical company that develops protein-based vaccines using its proprietary Trimer-Tag vaccine technology platform, with a focus on addressing significant respiratory viral diseases in older adult populations.
Average Trading Volume: 10,257,855
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.76B
For detailed information about 2197 stock, go to TipRanks’ Stock Analysis page.